uniQure Investors Face Deadline in Class Action Lawsuit

Kahn Swick & Foti, LLC Reminds Investors of April 13 Deadline to File Lead Plaintiff Applications

Apr. 12, 2026 at 6:34am

Got story updates? Submit your updates here. ›

A dramatic, high-contrast close-up of gears, levers, and other heavy industrial banking equipment, conveying the complex, powerful machinery of the financial system.An extreme close-up of the intricate mechanics behind the financial industry highlights the institutional forces at play in this securities lawsuit.NYC Today

Kahn Swick & Foti, LLC (KSF) is reminding investors who purchased shares of uniQure N.V. (NasdaqGS:QURE) between September 24, 2025 and October 31, 2025 that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against the company. The lawsuit alleges that uniQure failed to disclose material information during this period regarding the likelihood of its leading drug candidate, AMT-130, receiving accelerated approval from the FDA.

Why it matters

This case highlights the importance of transparency and accurate disclosures from publicly traded pharmaceutical companies, especially regarding the status of key drug candidates. Investors rely on this information to make informed decisions, and any failure to disclose material facts can lead to significant losses.

The details

The lawsuit alleges that during the Class Period, uniQure represented to investors that there was a high likelihood that AMT-130 would receive accelerated approval from the FDA after the company's planned Biologics License Application (BLA) submission in the first quarter of 2026. However, on November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 would be adequate to provide the primary evidence in support of a BLA submission, and as a result, the timing of the BLA submission was now unclear.

  • The Class Period is from September 24, 2025 to October 31, 2025.
  • Investors have until April 13, 2026 to file lead plaintiff applications in the lawsuit.

The players

uniQure N.V.

A biopharmaceutical company focused on developing gene therapies for rare and other devastating diseases.

Kahn Swick & Foti, LLC

A boutique securities litigation law firm that is representing investors in the class action lawsuit against uniQure.

Charles C. Foti, Jr.

The former Attorney General of Louisiana and a partner at Kahn Swick & Foti, LLC.

Got photos? Submit your photos here. ›

What they’re saying

“If you purchased shares of uniQure and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-qure/ to learn more.”

— Lewis Kahn, Managing Partner, Kahn Swick & Foti, LLC

What’s next

The judge will decide on April 13, 2026 whether to allow the class action lawsuit to proceed.

The takeaway

This case highlights the importance of pharmaceutical companies providing accurate and timely disclosures to investors, as any failure to do so can lead to significant losses for shareholders.